Literature DB >> 11429607

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.

A F Ochsenbein1, S Sierro, B Odermatt, M Pericin, U Karrer, J Hermans, S Hemmi, H Hengartner, R M Zinkernagel.   

Abstract

The vertebrate immune system has evolved to protect against infections that threaten survival before reproduction. Clinically manifest tumours mostly arise after the reproductive years and somatic mutations allow even otherwise antigenic tumours to evade the attention of the immune system. Moreover, the lack of immunological co-stimulatory molecules on solid tumours could result in T-cell tolerance; that is, the failure of T cells to respond. However, this may not generally apply. Here we report several important findings regarding the immune response to tumours, on the basis of studies of several tumour types. First, tumour-specific induction of protective cytotoxic T cells (CTLs) depends on sufficient tumour cells reaching secondary lymphatic organs early and for a long enough duration. Second, diffusely invading systemic tumours delete CTLs. Third, tumours that stay strictly outside secondary lymphatic organs, or that are within these organs but separated from T cells by barriers, are ignored by T cells but do not delete them. Fourth, co-stimulatory molecules on tumour cells do not influence CTL priming but enhance primed CTL responses in peripheral solid tumours. Last, cross priming of CTLs by tumour antigens, mediated by major histocompatibility complex (MHC) class I molecules of antigen-presenting host cells, is inefficient and not protective. These rules of T-cell induction and maintenance not only change previous views but also rationales for anti-tumour immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11429607     DOI: 10.1038/35082583

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  121 in total

Review 1.  Transplantation tolerance from a historical perspective.

Authors:  T E Starzl; R M Zinkernagel
Journal:  Nat Rev Immunol       Date:  2001-12       Impact factor: 53.106

2.  Heat-aggregated noninfectious influenza virus induces a more balanced CD8(+)-T-lymphocyte immunodominance hierarchy than infectious virus.

Authors:  Yunjung Cho; Sameh Basta; Weisan Chen; Jack R Bennink; Jonathan W Yewdell
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

3.  Early passenger leukocyte migration and acute immune reactions in the rat recipient spleen during liver engraftment: with particular emphasis on donor major histocompatibility complex class II+ cells.

Authors:  Toyokazu Okuda; Takashi Ishikawa; Olga Azhipa; Naoya Ichikawa; Anthony J Demetris; Thomas E Starzl; Noriko Murase
Journal:  Transplantation       Date:  2002-07-15       Impact factor: 4.939

Review 4.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 5.  A sense of tumour for the immune system.

Authors:  Stephen Todryk
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 6.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

7.  Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-activated fibroblasts.

Authors:  Xiuying Li; Yongsheng Wang; Yuwei Zhao; Hengxiu Yang; Aiping Tong; Chengjian Zhao; Huashan Shi; Yang Li; Zhenlin Wang; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-10       Impact factor: 4.553

8.  Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells.

Authors:  Vinod Singh; Qingyong Ji; Lionel Feigenbaum; Robert M Leighty; Arthur A Hurwitz
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

9.  Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.

Authors:  Jian Yan; Panyupa Pankhong; Thomas H Shin; Nyamekye Obeng-Adjei; Matthew P Morrow; Jewell N Walters; Amir S Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Cancer Immunol Res       Date:  2013-07-17       Impact factor: 11.151

Review 10.  New routes for allergen immunotherapy.

Authors:  Pål Johansen; Seraina von Moos; Deepa Mohanan; Thomas M Kündig; Gabriela Senti
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.